One of the questions we get most often during consultation is "Will it work for me?" We answer that question in writing every time, before any treatment is recommended. The answer is sometimes no.
This post is a quarter's worth of those conversations. Each case is anonymized and lightly composited to protect privacy, but the patterns are real and the recommendations we made were the recommendations we actually made.
We publish this for two reasons. First, because it's accountability we'd want from any clinic we sent our own family to. Second, because the willingness to say no is, in my view, the single best signal of whether a regenerative practice is doing medicine or running a sales operation.
Case 1: The grade-IV knee
A 71-year-old woman came in hoping to avoid a knee replacement her orthopedic surgeon had recommended. Imaging showed grade IV osteoarthritis with bone-on-bone changes, significant varus deformity, and subchondral cyst formation.
She had been told elsewhere that a "two-joint stem cell package" would let her cancel the surgery. The price was $19,000.
Our recommendation: proceed with the surgery her surgeon had recommended. The structural disease was beyond what cellular therapy realistically reverses, and the financial and biological cost of trying would be substantial.
She had the knee replacement. She's walking the dog at three months post-op.
Case 2: The patient who hadn't done PT
A 44-year-old recreational runner with 6 weeks of medial knee pain, no imaging, and no formal physical therapy. He wanted a PRP injection to "get back to running faster."
Our recommendation: hold off on injection. He hadn't fairly trialed conservative care, and the clinical picture suggested patellofemoral pain syndrome more than a structural injury that PRP would address. We sent him to a sports PT we trust with a note about strengthening priorities and a 6-week follow-up.
He returned three months later, pain-free, without any injection. He's still running.
Case 3: The systemic symptoms
A 58-year-old woman came in for joint pain in multiple sites: shoulders, hips, hands, feet. She wanted stem cell therapy for what another clinic had quoted as a $34,000 "whole body regen package."
Her exam, labs, and history were consistent with new-onset rheumatoid arthritis, not osteoarthritis. The pattern of involvement, morning stiffness duration, and inflammatory marker pattern strongly suggested a systemic autoimmune process that needed a rheumatologist.
Our recommendation: stop everything and see a rheumatologist before any regenerative protocol. Treating systemic autoimmune disease with intra-articular cells would not have addressed the actual problem, and could have delayed appropriate care.
She was diagnosed with seropositive RA, started on appropriate DMARD therapy with her rheumatologist, and is now doing well. We may or may not have a role in her care later. We didn't have one yet.
Case 4: The depression that wasn't ready for ketamine
A 36-year-old man, history of treatment-resistant depression on two failed SSRIs, wanted ketamine therapy. He had no psychiatrist of record, no current therapy relationship, and described active heavy alcohol use during a recent breakup.
Our recommendation: get a current psychiatrist established and pause the alcohol use before we'd consider ketamine. Subanesthetic ketamine in the context of active substance use disorder has a different risk profile than ketamine in a stable, supported patient. We weren't going to skip that step.
He pushed back. We held the line. He went elsewhere.
This is a case where the right answer for him long-term remained ketamine, possibly with us. But it wasn't going to be that day, and a clinic that said yes at that visit would not have been doing right by him.
Case 5: The patient with an unsuspected meniscal tear
A 52-year-old triathlete with chronic knee pain quoted at another clinic for a "moderate OA stem cell protocol" came to us for a second opinion. Her imaging, which she brought with her, hadn't been read carefully enough by the prior clinic.
A close look at her MRI showed a displaced bucket-handle meniscal tear, which explained the catching and intermittent locking she'd been describing. Stem cell injection wasn't going to solve that. It would have masked symptoms briefly while the mechanical pathology continued.
Our recommendation: surgical consultation for meniscal repair first, then consideration of post-op biologic support if appropriate.
She had the meniscal repair, came back to us four months later for a PRP series after the repair, and is back to triathlon training. The right answer was surgery first, regenerative second. Not the inverse.
Case 6: The patient who wanted a cure
A 67-year-old man with advanced multifocal cervical and lumbar spine degeneration, prior fusion at one level, ongoing radicular symptoms, and significant comorbid conditions. He wanted "the most aggressive stem cell protocol you have" and named a specific dollar amount he was willing to spend.
The honest answer is that there is no protocol where his clinical picture matches a reasonable expected response. His symptoms were structurally driven by anatomy a cellular protocol wouldn't change. The risk of letting his hope and his checkbook drive a protocol he didn't need was real.
Our recommendation: don't do regenerative therapy. Continue his current pain management with appropriate consultation from spine surgery for the surgical options that did make sense.
He was disappointed. We didn't take his money.
What these have in common
The cases above aren't dramatic refusals. They're routine clinical decisions made by anyone practicing medicine carefully. The reason they feel notable in the regenerative space is that the industry has normalized the opposite: a sales process that finds a way to say yes to almost every paying patient.
We don't think that's an industry standard worth aspiring to.
A few things to take from this:
- A clinic that has never said no is a clinic where the math always works out in their favor. That's not medicine.
- When we say no, we tell you why and we point you to where to go next. Sometimes it's a surgeon. Sometimes it's a rheumatologist. Sometimes it's a PT. Sometimes it's just "wait, this hasn't earned an intervention yet."
- A no from us isn't a permanent no. Several of the patients above returned to us later, for the right indication, after the right intervening step.
- A no costs us revenue today and probably earns us more revenue over a 10-year arc, because it earns us patients who actually trust the recommendation when we say yes.
If you've been quoted a protocol by another clinic and want a second opinion on whether it fits, request a consultation. We'll read the imaging, look at the workup, and tell you the truth. Sometimes the truth is that they're right. Sometimes it isn't. Either way, you'll know.